Ligand ID: VDN


Drugbank ID:
DB00862
(Vardenafil)


Indication:
Used for the treatment of erectile dysfunction

Get human targets for VDN in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'VDN' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.66A18.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6lu7 MAIN PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.62A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 12
LEU C 966
ILE C 973
SER B 974
PHE B 970
ILE B1169
1.65A20.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 11
ILE E1169
ALA E 972
ILE E 973
ILE D1169
PHE E 970
1.48A18.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.64A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6lzg SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU B 368
ILE B 358
SER B 399
PHE B 342
ILE B 434
1.76A21.45
None
None
None
NAG  B 601 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.64A23.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		5 / 12
LEU E 368
ILE E 358
SER E 399
PHE E 342
ILE E 434
1.67A21.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.62A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL B 202
ALA B 206
LEU B 208
MET B 264
PHE B 230
1.61A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL C 202
ALA C 206
LEU C 208
MET C 264
PHE C 230
1.66A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL D 202
ALA D 206
LEU D 208
MET D 264
PHE D 230
1.64A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.64A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ILE A 548
LEU A 862
VAL A 844
PHE A 441
ILE A 847
1.74A15.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
TYR A 787
LEU A 172
ILE A 171
ALA A 130
LEU A 127
1.68A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
ALA A 195
ILE A 201
VAL A  96
ALA A  97
PHE A 222
1.74A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
MET A 519
LEU A 372
MET B  90
PHE A 506
ILE A 562
1.76A17.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU A 368
ILE A 358
SER A 399
PHE A 342
ILE A 434
1.49A14.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE C 923
VAL C1065
PHE C1052
ILE C 931
PHE C 800
1.22A13.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU B 916
ILE B 923
VAL B1065
ILE B 931
PHE B 800
1.35A13.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
HIS C 207
TYR C  37
ALA C  93
GLY C  89
PHE C 194
1.65A13.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU B1012
ALA B1015
ILE B 770
ALA B 958
LEU B 962
1.54A15.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LEU A  73
ALA A  95
ILE A  86
ILE A 100
PHE A 123
1.53A22.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
LEU B 298
ILE B 296
VAL B 237
PHE B 233
1.44A22.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxs NSP3
(SARS-CoV-2)		5 / 10
HIS A  86
TYR A  68
ALA A  50
LEU A  43
GLY A  79
1.68A
None
None
None
None
SO4  A 201 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxs NSP3
(SARS-CoV-2)		5 / 10
HIS B  86
TYR B  68
ALA B  50
LEU B  43
GLY B  79
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
HIS B 207
TYR B  37
ALA B  93
GLY B  89
PHE B 194
1.75A13.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU B 916
ILE B 923
VAL B1065
ILE B 931
PHE B 800
1.38A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE B 923
VAL B1065
PHE B1052
ILE B 931
PHE B 800
1.23A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU B1012
ALA B1015
ILE B 770
ALA B 958
LEU B 962
1.59A15.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C 806
ILE C 794
SER B 711
PHE C 797
ILE C 882
1.43A13.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU B1012
ALA B1015
ILE B 770
ALA B 958
LEU B 962
1.62A15.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU A 916
ILE A 923
VAL A1065
ILE A 931
PHE A 800
1.38A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE C 923
VAL C1065
PHE C1052
ILE C 931
PHE C 800
1.24A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 10
LEU C 513
VAL C 524
ALA C 522
LEU C 390
PHE C 515
1.69A19.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
LEU C 368
ILE C 358
SER C 399
PHE C 342
ILE C 434
1.74A15.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.63A
None
None
None
None
SAM  A7104 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.64A
None
None
None
EDO  A7102 (-4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.69A
None
None
None
None
SAM  A7104 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
MET A6929
1.74A
None
None
None
EDO  A7102 (-4.8A)
SAM  A7104 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.63A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w6y NSP3
(SARS-CoV-2)		5 / 10
HIS B  86
TYR B  68
ALA B  50
LEU B  43
GLY B  79
1.74A
None
None
MES  B 201 ( 3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.67A17.13
None
None
None
None
SAM  C7105 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.72A17.13
None
None
None
None
SAM  A7102 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
PHE C6948
ILE C6955
1.65A17.13
None
None
None
FMT  C7115 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP10
(SARS-CoV-2)		5 / 10
LEU D4328
ALA D4277
VAL D4274
ALA B4279
PHE B4272
1.69A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.67A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.66A17.13
None
None
None
None
SAM  A7102 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 11
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.73A17.13
None
None
None
None
SAM  C7105 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ILE C 123
LEU C 178
ALA C 204
VAL C 242
PHE C 173
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 11
TYR B  83
ILE B 151
LEU B 132
ALA B 131
PHE B 147
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
TYR B  83
ILE B 151
LEU B 132
ALA B 131
PHE B 147
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
TYR C  83
ILE C 151
LEU C 132
ALA C 131
PHE C 147
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 123
LEU A 178
ALA A 204
VAL A 242
PHE A 173
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 11
ILE A 123
LEU A 178
ALA A 204
VAL A 242
PHE A 173
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 11
ILE C 123
LEU C 178
ALA C 204
VAL C 242
PHE C 173
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wcf NSP3
(SARS-CoV-2)		5 / 10
HIS A  86
TYR A  68
ALA A  50
LEU A  43
GLY A  79
1.74A
None
None
MES  A 201 ( 3.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU B 103
ALA B 150
ILE B 106
LEU A  17
MET A  62
1.69A16.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU A  60
ALA A  65
MET B  90
GLN B  88
PHE B  92
1.70A15.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU A  60
ALA A  65
VAL A  16
MET B  90
PHE B  92
1.43A15.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE F 304
LEU F 353
ILE F 357
ILE F 292
PHE F 286
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE F 304
LEU F 353
ILE F 357
ILE F 292
PHE F 286
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE A 304
LEU A 353
ILE A 357
ILE A 292
PHE A 286
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR C 298
LEU C 353
SER D 310
PHE C 286
ILE D 320
1.73A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE C 304
LEU D 331
ILE D 320
ILE C 292
PHE D 315
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE B 304
LEU A 331
ILE A 320
ILE B 292
PHE A 315
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE D 304
LEU D 353
ILE D 357
ILE D 292
PHE D 286
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR B 298
LEU B 353
SER A 310
PHE B 286
ILE A 320
1.72A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE C 304
LEU C 353
ILE C 357
ILE C 292
PHE C 286
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU C 331
ALA D 336
ILE D 337
ILE D 320
PHE C 314
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE E 304
LEU E 353
ILE E 357
ILE E 292
PHE E 286
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE B 304
LEU B 353
ILE B 357
ILE B 292
PHE B 286
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE D 304
LEU D 353
ILE D 357
ILE D 292
PHE D 286
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU F 331
ALA E 336
ILE E 337
ILE E 320
PHE F 314
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE A 304
LEU B 331
ILE B 320
ILE A 292
PHE B 315
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR E 298
LEU E 353
SER F 310
PHE E 286
ILE F 320
1.66A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE E 304
LEU E 353
ILE E 357
ILE E 292
PHE E 286
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE D 304
LEU C 331
ILE C 320
ILE D 292
PHE C 315
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE B 304
LEU B 353
ILE B 357
ILE B 292
PHE B 286
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
LEU C 331
ALA D 336
ILE D 337
ILE D 320
PHE C 314
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE A 304
LEU A 353
ILE A 357
ILE A 292
PHE A 286
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE D 304
LEU C 331
ILE C 320
ILE D 292
PHE C 315
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE C 304
LEU C 353
ILE C 357
ILE C 292
PHE C 286
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
LEU F 331
ALA E 336
ILE E 337
ILE E 320
PHE F 314
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR D 298
LEU D 353
SER C 310
PHE D 286
ILE C 320
1.68A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR A 298
LEU A 353
SER B 310
PHE A 286
ILE B 320
1.70A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE B 304
LEU A 331
ILE A 320
ILE B 292
PHE A 315
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR F 298
LEU F 353
SER E 310
PHE F 286
ILE E 320
1.72A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE E 304
LEU F 331
ILE F 320
ILE E 292
PHE F 315
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.66A
None
None
None
None
SAH  C7102 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
PHE C6948
ILE C6955
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.73A
None
None
None
None
SAH  C7102 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.74A
None
None
None
None
SAH  A7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
MET A6929
1.80A
None
None
None
None
SAH  A7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt NSP10
(SARS-CoV-2)		5 / 10
LEU D4328
ALA D4277
VAL D4274
ALA B4279
PHE B4272
1.70A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.68A
None
None
None
None
SAH  A7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.67A
None
None
None
None
SFG  A7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP10
(SARS-CoV-2)		5 / 10
LEU D4328
ALA D4277
VAL D4274
ALA B4279
PHE B4272
1.70A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 11
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.72A
None
None
None
None
SFG  C7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.65A
None
None
None
None
SFG  C7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
PHE C6948
ILE C6955
1.67A
None
None
None
FMT  C7105 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.73A
None
None
None
None
SFG  A7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
LEU B 228
ILE B 223
VAL B 339
PHE B 233
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
LEU B 332
VAL B 321
ILE B 296
PHE B 342
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE A 328
LEU A 298
ILE A 306
MET A 331
PHE A 330
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE A 307
LEU A 228
ILE A 223
VAL A 339
PHE A 233
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE B 307
LEU B 228
ILE B 223
VAL B 339
PHE B 233
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE A 307
LEU A 332
VAL A 321
ILE A 296
PHE A 342
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 10
LEU B 228
ILE B 223
VAL B 237
LEU B 215
PHE B 222
1.67A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
HIS A 250
LEU A 255
ILE A 253
ILE A 223
MET A 219
1.58A
U5P  A 401 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 10
LEU A 228
ILE A 223
VAL A 237
LEU A 215
PHE A 222
1.63A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
ILE B 223
VAL B 237
PHE B 303
ILE B 253
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A 307
LEU A 228
ILE A 223
VAL A 339
PHE A 233
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
HIS B 250
LEU B 255
ILE B 253
ILE B 223
MET B 219
1.57A
U5P  B 401 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
LEU B 298
ILE B 296
VAL B 237
PHE B 233
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LEU A  73
ALA A  95
ILE A  86
ILE A 100
PHE A 123
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 10
TYR B  89
LEU B 163
ILE B  64
ALA B  95
LEU B  73
1.77A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A 307
LEU A 298
ILE A 296
VAL A 237
PHE A 233
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
LEU A  73
ALA A  95
ILE A  86
ILE A 100
PHE A 123
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
HIS A 250
LEU A 255
ILE A 253
ILE A 223
MET A 219
1.57A
U5P  A 401 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
LEU B  73
ALA B  95
ILE B  86
ILE B 100
PHE B 123
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
HIS B 250
LEU B 255
ILE B 253
ILE B 223
MET B 219
1.59A
U5P  B 401 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 10
TYR A  89
LEU A 163
ILE A  64
ALA A  95
LEU A  73
1.75A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LEU B  73
ALA B  95
ILE B  86
ILE B 100
PHE B 123
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A 328
LEU A 298
ILE A 306
MET A 331
PHE A 330
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A 307
LEU A 332
VAL A 321
ILE A 296
PHE A 342
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.65A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE D  18
LEU D 140
ALA D 129
VAL D 155
ILE D  23
1.76A
None
None
APR  D 201 (-3.7A)
None
APR  D 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
ILE D  18
LEU D 140
ALA D 129
VAL D 155
ILE D  23
1.69A
None
None
APR  D 201 (-3.7A)
None
APR  D 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 10
HIS A  86
TYR A  68
ALA A  50
LEU A  43
GLY A  79
1.71A
None
None
APR  A 201 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.72A
None
None
APR  A 201 (-3.7A)
None
APR  A 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE C  18
LEU C 140
ALA C 129
VAL C 155
ILE C  23
1.77A
None
None
APR  C 201 (-3.7A)
None
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.78A
None
None
APR  A 201 (-3.7A)
None
APR  A 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE B  18
LEU B 140
ALA B 129
VAL B 155
ILE B  23
1.75A
None
None
APR  B 201 (-3.7A)
None
APR  B 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
ILE B  18
LEU B 140
ALA B 129
VAL B 155
ILE B  23
1.68A
None
None
APR  B 201 (-3.7A)
None
APR  B 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.65A
None
None
None
None
SAH  A7101 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.71A
None
None
None
None
SAH  A7101 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
MET A6929
1.78A
None
None
None
None
SAH  A7101 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
TYR B 149
ILE B 119
ALA B 102
LEU B  95
MET A  52
1.78A16.09
None
None
EDO  B 302 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
TYR D 149
ILE D 119
ALA D 102
LEU D  95
MET C  52
1.79A16.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU D 103
ALA D 150
ILE D 106
LEU C  17
MET C  62
1.62A16.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU B 103
ALA B 150
ILE B 106
LEU A  17
MET A  62
1.64A16.09
None
EDO  B 302 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.68A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
ILE A 123
LEU A 178
ALA A 204
VAL A 242
PHE A 173
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 11
TYR A  83
ILE A 151
LEU A 132
ALA A 131
PHE A 147
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 11
ILE A 123
LEU A 178
ALA A 204
VAL A 242
PHE A 173
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
TYR A  83
ILE A 151
LEU A 132
ALA A 131
PHE A 147
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.65A18.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
LEU A  60
ALA A  65
VAL A  16
MET B  90
PHE B  92
1.14A12.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU A  60
ALA A  65
VAL A  16
MET B  90
PHE B  92
1.20A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
LEU D 103
ALA D 150
ILE D 106
LEU C  17
MET C  62
1.65A15.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
LEU B 103
ALA B 150
ILE B 106
LEU A  17
MET A  62
1.67A15.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
LEU A  60
ALA A  65
VAL A  16
MET B  90
PHE B  92
1.19A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU E 368
ILE E 358
SER E 399
PHE E 342
ILE E 434
1.79A19.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR E 380
LEU E 425
ALA E 411
ILE E 410
LEU E 368
1.73A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU A 368
ILE A 358
SER A 399
PHE A 342
ILE A 434
1.79A19.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU A 513
VAL A 524
ALA A 522
LEU A 390
PHE A 515
1.66A19.24
None
None
None
DMS  A 905 (-4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU E 513
VAL E 524
ALA E 522
LEU E 390
PHE E 515
1.62A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR A 380
LEU A 425
ALA A 411
ILE A 410
LEU A 368
1.76A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR E 380
LEU E 425
ALA E 411
ILE E 410
LEU E 368
1.76A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU E 368
ILE E 358
SER E 399
PHE E 342
ILE E 434
1.66A19.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU E 513
VAL E 524
ALA E 522
LEU E 390
PHE E 515
1.59A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.67A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU A 513
VAL A 524
ALA A 522
LEU A 390
PHE A 515
1.63A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU E 368
ILE E 358
SER E 399
PHE E 342
ILE E 434
1.79A19.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR A 380
LEU A 425
ALA A 411
ILE A 410
LEU A 368
1.73A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU A 368
ILE A 358
SER A 399
PHE A 342
ILE A 434
1.79A19.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU E 513
VAL E 524
ALA E 522
LEU E 390
PHE E 515
1.61A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR E 380
LEU E 425
ALA E 411
ILE E 410
LEU E 368
1.73A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ALA A 206
PHE A   8
ILE A 106
GLN A 110
PHE A 294
1.78A
None
None
None
PEG  A 405 ( 3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.67A23.22
PEG  A 405 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
HIS A 119
TYR A  68
ALA A 112
LEU A  75
GLN D 118
1.77A
None
None
None
None
EDO  D 201 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
LEU D  75
ILE D  69
LEU D  53
MET D  61
GLN D  62
1.67A18.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.62A
None
None
APR  A 201 ( 3.7A)
APR  A 201 ( 4.8A)
APR  A 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE D  18
LEU D 140
ALA D 129
VAL D 155
ILE D  23
1.71A
None
None
APR  D 201 (-3.4A)
None
APR  D 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE E  18
LEU E 140
ALA E 129
VAL E 155
ILE E  23
1.72A
None
None
APR  E 201 (-3.5A)
APR  E 201 ( 4.9A)
APR  E 201 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
LEU D  75
ILE D  69
LEU D  53
MET D  61
GLN D  62
1.65A18.51
EDO  D 202 (-4.6A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE B  18
LEU B 140
ALA B 129
VAL B 155
ILE B  23
1.62A
None
None
APR  B 201 (-3.6A)
None
APR  B 201 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.68A
None
None
APR  A 201 ( 3.7A)
APR  A 201 ( 4.8A)
APR  A 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE B  18
LEU B 140
ALA B 129
VAL B 155
ILE B  23
1.68A
None
None
APR  B 201 (-3.6A)
None
APR  B 201 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE C  18
LEU C 140
ALA C 129
VAL C 155
ILE C  23
1.67A
None
None
APR  C 201 (-3.6A)
APR  C 201 ( 4.9A)
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE D  18
LEU D 140
ALA D 129
VAL D 155
ILE D  23
1.65A
None
None
APR  D 201 (-3.4A)
None
APR  D 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
LEU B  75
ILE B  69
LEU B  53
MET B  61
GLN B  62
1.67A18.51
None
None
None
None
EDO  B 202 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE C  18
LEU C 140
ALA C 129
VAL C 155
ILE C  23
1.60A
None
None
APR  C 201 (-3.6A)
APR  C 201 ( 4.9A)
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE C  18
LEU C 140
ALA C 129
VAL C 155
ILE C  23
1.78A
None
None
None
EDO  C 206 ( 4.2A)
EDO  C 206 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
HIS C 119
TYR C  68
ALA C 112
LEU C  75
GLN A 118
1.78A
None
None
None
None
EDO  A 202 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
HIS C  86
TYR C  68
ALA C  50
LEU C  43
GLY C  79
1.68A
None
None
MES  C 201 ( 3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
HIS A 119
TYR A  68
ALA A 112
LEU A  75
GLN C 118
1.76A
None
None
None
None
EDO  A 204 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.62A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7btf NSP12
(SARS-CoV-2)		5 / 12
TYR A  87
HIS A  99
PHE A 219
ILE A 201
MET A 196
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7btf NSP12
(SARS-CoV-2)		5 / 10
ALA A 195
ILE A 201
VAL A  96
ALA A  97
PHE A 222
1.78A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7btf NSP12
NSP7
(SARS-CoV-2)		6 / 10
HIS C  36
TYR A 420
ALA A 550
PHE A 440
LEU A 437
GLY A 841
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
MET A 519
LEU A 372
MET B  90
PHE A 506
ILE A 562
1.73A17.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7btf NSP12
(SARS-CoV-2)		5 / 10
TYR A 787
LEU A 172
ILE A 171
ALA A 130
LEU A 127
1.67A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.63A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
ALA A 195
ILE A 201
VAL A  96
ALA A  97
PHE A 222
1.77A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv1 NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU D 103
ALA D 150
ILE D 106
LEU C  17
MET C  62
1.57A18.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
TYR A  87
HIS A  99
PHE A 219
ILE A 201
MET A 196
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
TYR A 787
LEU A 172
ILE A 171
ALA A 130
LEU A 127
1.68A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
ALA A 195
ILE A 201
VAL A  96
ALA A  97
PHE A 222
1.76A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 787
LEU A 172
ILE A 171
ALA A 130
LEU A 127
1.66A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 12
MET A 519
LEU A 372
MET B  90
PHE A 506
ILE A 562
1.80A17.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
NSP7
(SARS-CoV-2)		6 / 10
HIS C  36
TYR A 420
ALA A 550
PHE A 440
LEU A 437
GLY A 841
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 122
TYR A 175
ALA A 125
LEU A 131
GLY A 179
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
TYR A  87
HIS A  99
PHE A 219
ILE A 201
MET A 196
1.70A
None